Skip to main content
SpringerLink
Log in

Radiolabeled Monoclonal Antibodies for Localization and Treatment of Metastatic Cancer

  • Chapter
Principles of Cancer Biotherapy

  • 107 Accesses

Abstract

Current diagnostic imaging procedures are commonly used to view a circumscribed part of the body such as head or thorax. Conventional nuclear medicine imaging procedures such as bone scans may be directed at an organ system, but only recently have single diagnostic imaging procedures become available to search the entire body and all tissues simultaneously for tumor deposits. Antibodies to tumor associated antigens, and ligand-receptor based imaging agents, such as the recently approved somatostatin receptor binding peptide,111 In pentetreotide, offer the opportunity to image tumors directly. Other radiolabeled imaging agents, such as 201 thallium, 99mTc-MIBI and positron emitters such as 18F-fluorodeoxyglucose (FDG) localize in areas of increased cellularity, vascularity or increased metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abrams P, Fer M, Faubion C, et al. A new procedure for staging small cell lung cancer (SCLC): gamma camera imaging using a technetium-99m labeled monoclonal antibody Fab. Am Soc Clin Oncol 1990; 9: A895.

    Google Scholar 

  2. Abrams PG, Morgan AC, Schroff RW, et al. Localization and biodistribution studies of a monoclonal antibody in patients with melanoma. In: Reisfeld, Sell, eds. Monoclonal antibodies and cancer therapy. New York: Alan R. Liss, 1985:233–236.

    Google Scholar 

  3. Abrams P, Oldham R. Monoclonal antibody therapy of solid tumors. In: Foon KA, Morgan AC Jr, eds. Monoclonal antibody therapy of human cancer. Boston: Martinus Nijhoff, 1985: 103–120.

    Chapter  Google Scholar 

  4. Abrams PG, Rossio JR, Stevenson HC, Foon KA. Optimal strategies for developing human monoclonal antibodies. Methods Enzymol 1986; 121: 107–119.

    Article  PubMed  CAS  Google Scholar 

  5. Adelstein SJ, Kassis Al. Radiobiologic implications of the microscopic distribution of energy from radionuclides. Nucl Med Biol 1987; 14: 165–169.

    CAS  Google Scholar 

  6. Arnold MW, Schneebaum S, Berens A, Mojzisik C, Hinkle G, Martin EW Jr. Radioimmunoguided surgery challenges traditinal decision making in patients with primary colorectal cancer. Surgery 1992; 112: 624–630.

    PubMed  CAS  Google Scholar 

  7. Appelbaum FR, Matthews DC, Eary JF, et al. Use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992; 54: 829–833.

    Article  PubMed  CAS  Google Scholar 

  8. Axworthy DB, Fritzberg AR, Hylarides MD, et al. Preclinical evaluation of an anti-tumor monocloncal/ streptavidin conjugate for pretargeted 90Y radioimmunotherapy in a mouse xenograft model. J Immunother 1994; 16(2) 158.

    Article  Google Scholar 

  9. Beaumier PL, Vanderheyden J-L, Venkatesan P, et al. Concurrent 186Re radioimmunotherapy and chemotherapy of experimental small cell lung carcinoma. Antibody, Immunoconjugates and Radiopharmaceuticals 1991; 4(4) 735–744.

    Google Scholar 

  10. Bierman PJ, Vose JM, Leichner PK et al. Yttrium-90- labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor prognostic Hodgkin’s disease. J Clin Oncol 1993; 11: 698–703

    PubMed  CAS  Google Scholar 

  11. Bierwaltes WH. Radioimmunotherapy of cancer: Historical perspectives and prospects for the future. Text of talk delivered at the NATO Conference on Radiolabeled monoclonal antibody and external scintigraphy. Science 1979; 206: 844–847.

    Article  Google Scholar 

  12. Biggi A, Gianfranco B, Ferrigno D et al. Detection of suspected primary lung cancer by scintigraphy with Indium- 111-anti-carcinoembryonic antigen monoclonal antibodies (type F023C5). J Nucl Med 1991; 32(11) 2064–2068.

    PubMed  CAS  Google Scholar 

  13. Brandt KD, Johnson DK: Structure-function relationships in indium-Ill radioimmunoconjugates. Bioconjugate Chem 1992; 3: 118–125.

    Article  CAS  Google Scholar 

  14. Breitz HB, Weiden PL, Vanderheyden J-L, et al. Clinical experience with Re-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials. J Nucl Med 1992; 33: 1099–1112.

    PubMed  CAS  Google Scholar 

  15. Breitz HB, Fisher DR, Weiden PL, et al. Dosimetry of Rhenium-186-labeled monoclonal antibodies: Methods, predictions from technetium-99m-labeled antibodies and results of phase I trials. J Nucl Med 1993; 34 (6) 908–917.

    PubMed  CAS  Google Scholar 

  16. Breitz HB, Sullivan K, Nelp WB. Imaging lung cancer with radiolabeled antibodies. Seminars in Nuclear Medicine 1993; 23(2) 127–132.

    Article  PubMed  CAS  Google Scholar 

  17. Breitz HB, Durham JS, Fisher DR, et al. Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody. J Nucl Med 1995; 36(5) 754–761.

    PubMed  CAS  Google Scholar 

  18. Breitz HB, Seiler C, Weiden P, et al. Re-186 16.88 IgM and 88BV69 IgG human antibody studies to assess potential for radioimmunotherapy. J Nucl Med 1994; 34(5): 100P.

    Google Scholar 

  19. Buraggi G, Turrin A, Bombardiere E, et al. Immunoscintigraphy of colorectal carcinoma with F(ab’)2 fragments of anti-CEA monoclonal antibody. Cancer Detect Prev 1987; 10: 335–345.

    PubMed  CAS  Google Scholar 

  20. Camera L, Kinuya S, Garmestani K, et al. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)- 6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz) -1,4,7, 10-tetraazacyclododecane tetraacetic acid (2B-DOTA). Eur J Nucl Med 1994; 21: 640–646.

    Article  PubMed  CAS  Google Scholar 

  21. Carrasquillo JA, Krohn KA, Beaumier P, et al. Diagnosis and treatment for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treatment Report 1984; 68:317–328.

    CAS  Google Scholar 

  22. Carrasquillo JA, Abrams PG, Schroff RW, Reynolds JC, et al. Effect of11 lIn-9.2.27 monoclonal antibody dose on the imaging of metastatic melanoma. J Nucl Med 1987; 26: 67.

    Google Scholar 

  23. Carrasquillo JA, Sugarbaker P, Colcher D, et al. Radioimmunoscintigraphy of colon cancer with iodine-131- labeled B72.3 monoclonal antibody. J Nucl Med 1988; 29: 1022–1030.

    PubMed  CAS  Google Scholar 

  24. Cheung N-K., Landmeier B, et al. Complete tumor ablation with 131I-labeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. JNCI 1986; 77: 739–745.

    PubMed  CAS  Google Scholar 

  25. Cheung N-K, Munn D, Kushner BH, Usmani N, Yeh SD. Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies. Int J Rad Appl Instrum (B) 1989; 16:111–120.

    CAS  Google Scholar 

  26. Colcher D, Esteban J, Carrasquillo JA, et al. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Research 1987; 47:4218–4224.

    PubMed  CAS  Google Scholar 

  27. Collier BD, Abdel-Nabi H, Doerr RJ, et al. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CI. Radiol 1992; 185(1) 179–186.

    CAS  Google Scholar 

  28. Czucman MS, Nabi HA, Meredith RM, et al. Radioimmunotherapy of B-cell lymphomas with iodine-131- labeled LL2 monoclonal antibody. J Immunother 1994; 16(2) 160 (abs)

    Article  Google Scholar 

  29. DeJager R, Abdel-Nabi H, Serafini A, Pecking A, Klein J, Hanna MG. Current status of cancer immunodetection with radiolabeled human monoclonal antibodies. Semin Nucl Med 1993; 23(2) 165–179..

    Article  CAS  Google Scholar 

  30. Delaloye B, Bischof-Delaloye A, Buchegger F, et al. Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab’)2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J Clin Invest 1986; 77: 301–311.

    Article  PubMed  CAS  Google Scholar 

  31. DeNardo S, DeNardo G, O’Grady LF. Chronic lymphocytic leukemia and non-Hodgkins’ lymphoma. Front Radiat Ther Oncol 1989; 24: 18

    Google Scholar 

  32. DeNardo GL, DeNardo SJ, O’Grady LF, Levy NB, Adams GP, Mills SL. Fractionated radioimmunotherapy of B-cell malignancies with 131-Lym-l. Cancer Res 1990; 50: 1014s–1016s.

    PubMed  CAS  Google Scholar 

  33. DeNardo GL, DeNardo SJ, Meares CF et al. Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate in mice and in patients with lymphoma. Antibod Immunoconjug and Radiopharm 1991; 4: 777–785.

    CAS  Google Scholar 

  34. DeNardo GL, DeNardo SJ, Kukis D et al. Strategies for enhancement of radioimmunotherapy. Nucl Med Biol 1991; 18:633–640..

    CAS  Google Scholar 

  35. DeNardo SJ, O’Grady LF, Warhoe KA, Kroger LA, Hellstrom I, Hellstrom KE, Maddock SW, et al. Radioimmunotherapy in patients with metastatic breast cancer. J Nucl Med 1992; 33(5): 862Abstr

    Google Scholar 

  36. DeNardo GL, Maddock SW, Sgouros G, Scheibe PO, DeNardo SJ. Immunoadsorption: An enhancement strategy for radioimmunotherapy. J Nucl Med 1993; 6: 1020–1027.

    Google Scholar 

  37. DeNardo SJ, Mirick GR, Kroger LA et al. The Biologic window for chimeric L6 radioimmunotherapy. Cancer suppl 1994; 73: 1023–1032.

    CAS  Google Scholar 

  38. Dillehay LE, Williams JR. Radiobiology of dose-rate patterns achievable in radioimmunoglobulin therapy. In: The Present and Future Role of Monoclonal Antibodies in the Management of Cancer. Front Radiat Ther Oncol. Vaeth JM, Meyer JL, Eds. Karger, Basel, 1990; 24: 96–103.

    Google Scholar 

  39. Dillman RO. Human antimouse and antiglobulin responses to monoclonal antibodies. Antibody, Immunoconjugates, and Radiopharmaceuticals 1990; 3(1) 1–15.

    Google Scholar 

  40. Divgi CR, Larson SM. Radiolabeled monoclonal antibodies in the diagnosis and treatment of malignant melanoma. Seminars in Nucl Med 1989; 19(4) 252–261.

    Article  CAS  Google Scholar 

  41. Divgi CR, McDermott K, Griffin TW, et al. Lesion-bylesion comparison of computerized tomography and indium- 111-labeled monoclonal antibody CI 10 radioimmunoscintigraphy in colorectal carcinoma: A multicenter trial. J Nucl Med 1993; 34:1656–1661.

    PubMed  CAS  Google Scholar 

  42. Epenetos AA, Mather S, Granowska M, et al. Targeting of iodine-123-labeled tumor-associated monoclonal antibodies to ovarian, breast and gastrointestinal tumors. Lancet 1982; II: 999–1004.

    Article  Google Scholar 

  43. Epenetos AA. Combined radiolabeled antibodies and radiotherapy for the treatment of head and neck cancer. J Immunother 1994; 16(2) 163 (abs).

    Article  Google Scholar 

  44. Epenetos AA, Snook D, Durbin H et al Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Research 1986; 46: 3183–3191.

    PubMed  CAS  Google Scholar 

  45. Fairweather DS, Bradwell AR, Dykes PW, Vaughan AT, Watson-James SF, Chandler S. Improved tumor localization using indium-111 labelled antibodies. British Med J1983; 287: 167–170..

    Article  CAS  Google Scholar 

  46. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Br J Radiat Oncol Biol Phys 1990: 18: 1261–1269.

    Article  CAS  Google Scholar 

  47. Friedman S, Sullivan K, Salk D, et al. Staging non-small cell carcinoma of the lung using Technetium-99m-labeled monoclonal antibodies. Hematology/Oncology Clinics of North America 1990; 4(6) 1069–1078.

    PubMed  CAS  Google Scholar 

  48. Fritzberg AR, Beaumier PL, Bottino BJ, Reno JR. Approaches to improved antibody- and peptide-mediated targeting for imaging and therapy of cancer. J Controlled Release 1994; 28: 167–173.

    Article  CAS  Google Scholar 

  49. Fritzberg AR, Wilbur DS. Radiolabeled antibodies for targeted diagnostics. In: Targeted Delivery of Imaging Agents. Ed. V Torchilin, CRC Press, Boca Raton, in press.

    Google Scholar 

  50. Fritzberg AR, Vanderheyden J-L, Morgan AC, Schroff RW, Abrams PG. Rhenium-186/-188 labeled antibodies for radioimmunotherapy. In: Technetium and Rhenium in Chemistry and Nuclear Medicine. Cortina Intl., Verona, pp615–621,1990.

    Google Scholar 

  51. Fritzberg AR, Berninger RW, Hadley SW, Wester DW. Approaches to radiolabeling of antibodies for diagnosis and therapy of cancer. Pharm Res 1988; 5: 325–334.

    Article  PubMed  CAS  Google Scholar 

  52. Fritzberg AR, Abrams PG, Beaumier PL, et al. Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent. Proc Natl Acad Sci 1988; 85:4025–4029

    Article  PubMed  CAS  Google Scholar 

  53. Gallinger S, Reilly RM, Kirsh JC et al. Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Research 1993; 53: 271–278.

    PubMed  CAS  Google Scholar 

  54. Gansow OA. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Nucl Med Biol 1991; 18:369–381.

    CAS  Google Scholar 

  55. Goldenberg DM, Kim EE, DeLand FH, et al. Clinical radioimmunodetection of cancer with radioactive antibodies to human chorionic gonadotropin. Science 1980; 208: 1284–1286.

    Article  PubMed  CAS  Google Scholar 

  56. Goodman GE, Hellstrom I, Yelton DE, et al. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small cell lung, colon, and breast cancer. Cancer Immunol Immunother 1993: 36: 267–273.

    Article  PubMed  CAS  Google Scholar 

  57. Goodwin DA, Meares CF, McCall MJ, et al. Pretargeted immunoscintigraphy of murine tumors with indium-111- labeled bifunctional haptens. J Nucl Med 1988; 29: 266–334

    Google Scholar 

  58. Goodwin DA, Meares CF, Watanabe N et al. Pharmacokinetics of pretargeted monoclonal antibody 2D 12.5 and 90Y-Janus-2(p-nitrobenzyl)-l, 4, 7, 10-tetraazacyclododecanetetraacetic acid(DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: A model for radioimmunotherapy. Cancer Res 1994; 54: 5937–5946.

    PubMed  CAS  Google Scholar 

  59. Goodwin DA. Tumor pretargeting: Almost the bottom Xine. J Nucl Med 1995; 36(5) 876–879.

    PubMed  CAS  Google Scholar 

  60. Griffiths GL, Goldenberg DM, Jones AL, Hansen HJ. Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium. Bioconj Chem 1992; 3:91–99.

    Article  CAS  Google Scholar 

  61. Hird V, Stewart JSW, Snook D, et al. Intraperitoneally administered 90Y-labeled monoclonal antibodies as a third line of treatment in ovarian cancer, a phase 1-2 trial: problems encountered and possible solutions. Br J Cancer 1990; 10:48–51.

    CAS  Google Scholar 

  62. Hnatowich DJ. Recent developments in the radiolabeling of antibodies with iodine, indium, and technetium. Sem Nucl Med 1990; 20: 80–91,

    Article  CAS  Google Scholar 

  63. Howell RW, Dandamudi V, Rao, Sastry KSR. Macroscopic dosimtry for radioimmunotherapy: Nonuniform activity distributions in solid tumors. Med Phys 1989; 16: 66–74.

    Article  PubMed  CAS  Google Scholar 

  64. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986; 27: 10–1497.

    Google Scholar 

  65. Huse WD, Sastry L, Iverson SA, et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage. Science 1989; 246: 1275–1281.

    Article  PubMed  CAS  Google Scholar 

  66. Jacobs AJ, Fer M, Su F-M, et al. A phase I trial of a rhenium-186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: Toxicity and clinical response. Obstet Gynecol 1993; 82: 586–593.

    Article  PubMed  CAS  Google Scholar 

  67. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988; 48: 2641–2658.

    PubMed  CAS  Google Scholar 

  68. James K. Human monoclonal antibodies and engineered antibodies in the management of cancer. Semin Cancer Biol 1990; 1:243–253.

    PubMed  CAS  Google Scholar 

  69. Kalofonos HP, Sivolapenko GB, Courtney-Luck NS, et al. Antibody guided targeting of non-small cell lung cancer using 1HIn-labeled HMFG1 F(ab’)2 fragments. Cancer Res 1988; 48: 1977–1984.

    PubMed  CAS  Google Scholar 

  70. Kalofonos HP, Rusckowski M, Siebecker DA, et al. Imaging of tumor in patients with In-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med 1990; 31: 1791–1796

    PubMed  CAS  Google Scholar 

  71. Kalofonos HP, Rowlinson G, Epenetos AA. Enhancement of antibody uptake in human colon xenografts following irradiation. Can Res 1990; 50: 159–163..

    CAS  Google Scholar 

  72. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymnphoma with [131I]anti-BI (anti-CD20) antibody. N Engl J Med 1993; 329(7) 459–465.

    Article  PubMed  CAS  Google Scholar 

  73. King DJ, Turner A, Farnsworth APH., et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Research 1994; 54: 6176–6185.

    PubMed  CAS  Google Scholar 

  74. Klein JL, Leichner PK, Callahan KM, Laphar KA, Order SE. Effects of anti-antibodies on radiolabeled antibody therapy. Antibody Immunocon Radiopharm 1988; 1: 55–64.

    Google Scholar 

  75. Kosmas C, Maraveyas A, Gooden CS, Snook D, Epenetos A. Anti-chelate antibodies after intraperitoneal yttrium- 90-labeled antibody immunoconjugates for ovarian cancer therapy. J Nucl Med 1995; 36(5) 746–753.

    PubMed  CAS  Google Scholar 

  76. Krag DN, Haseman MK, Ford P, et al. Gamma probe location of 11 indium-labeled B72.3: An extension of immunoscintigraphy. Journ Surg Oncol 1992; 51: 226–230.

    Article  CAS  Google Scholar 

  77. Kramer EL, Larson SM. Tumor targeting with radiolabeled anti-body for diagnosis and therapy. Immunology and Allergy Clinics of North America 1991; 11(2) 301–339.

    Google Scholar 

  78. Krishnamurthy S, Morris JF, Antonovic R, Ahmed A, Galey WT, Duncan C, Krishnamurthy GT. Evaluation of primary lung cancer with Indium 111 anti-carcinoembryonic antigen (Type ZCE-025) monoclonal antibody scintigraphy. Cancer 1990; 65:458–465.

    Article  PubMed  CAS  Google Scholar 

  79. Langmuir VK. Radioimmunotherapy: Clinical results and dosimetric considerations. Nucl Med Biol 1992; 19: 213–225.

    CAS  Google Scholar 

  80. Larson SM, Brown JP, Wright BW, et al. Imaging of melanoma with I-131-labeled antibodies. J Nucl Med 1983; 127:539–546.

    Google Scholar 

  81. Larson SM, Carrasquillo JA, Krohn KA, Brown JP, et al. Localization of 131I-labeled p97 specific Fab fragments in human melanomas as a basis for radiotherapy. J Clin Invest 1983; 72: 2101–2114.

    Article  PubMed  CAS  Google Scholar 

  82. Larson SM. Radioimmunology: Imaging and therapy. Cancer Suppl 1991; 67: 1253–1260.

    CAS  Google Scholar 

  83. Lashford LS, Davies AG, Richardson RB, et al. A pilot study of 1311 monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer 1988; 61: 857–868.

    Article  PubMed  CAS  Google Scholar 

  84. LeDoussal J-M, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: Enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989; 30: 1358–1366.

    CAS  Google Scholar 

  85. Ledermann JA, Begent RHJ., Massof C, Kelly AMB, Adam T, Bagshawe KD. A phase-I study of repeated therapy with radiolabed antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int J Cancer 1991; 47: 659–664.

    Article  PubMed  CAS  Google Scholar 

  86. Leitha T, Walter R, Schlick W, Dudczak R. 99mTc-Anti- CEA radioimmunoscintigraphy of lung adenocarcinoma. Chest 1991; 99: 14–19.

    Article  PubMed  CAS  Google Scholar 

  87. Lenhard RE, Order SE, Spunberg JJ, et al. Isotopic immunoglobulin: A new systemic therapy for advanced Hodgkin’s disease. J Clin Oncol 1985; 3: 1296.

    PubMed  Google Scholar 

  88. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA 1989; 86:4220–4224.

    Article  PubMed  CAS  Google Scholar 

  89. Mach JP, Bucheggar F, Forni M, et al. Use of radiolabeled monocolnoal anti-CEA antibodies for detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol Today 1981; 2: 239–249.

    Article  Google Scholar 

  90. Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radiobiology of a-particle radioimmunotherapy: Induction of apoptosis. Radiat Res 1992; 130: 220–226.

    Article  PubMed  CAS  Google Scholar 

  91. Maguire RT, Schmelter RF, Pascucci VL et al. Immunoscintigraphy of colorectal adenocarcinoma: Results with site specific radiolabeled B72.3 (111In-CYT-103). Antibod ImmunoconjRadiopharm 1989; 2: 257–269.

    Google Scholar 

  92. Mattes, MJ, Griffiths, GL, Diril, H, et al. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer 1994; 73: 787–793.

    Article  PubMed  CAS  Google Scholar 

  93. Matthews DC, Appelbaum FR, Eary et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoeitic irradiation delivered by 131I labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995; 85(4) 1122–1131.

    PubMed  CAS  Google Scholar 

  94. Meredith RM, Khazaeli MB, Plott WE, et al. Phase I trial of iodine-131-chimeric B72.3 in metastatic colorectal cancer. J Nucl Med 1992; 33: 23–29.

    PubMed  CAS  Google Scholar 

  95. Miraldi FD, Nelson AD, Kraly C, et al. Diagnostic imaging of human neuroblastoma with radiolabeled antibody. Radiology 1986; 161:413–418.

    PubMed  CAS  Google Scholar 

  96. Modorati G, Brancato R, Paganelli G, Magnani P, Pavoni R, Fazio F. Immunoscintigraphy with three step monoclonal pretargeting technique in diagnosis of uveal melanoma: preliminary results. Br J Ophthalmol 1994; 78(1) 19–23.

    Article  PubMed  CAS  Google Scholar 

  97. Moffat FL, Vargas-Cuba RD, Serafini AN et al. Preoperative scintigraphy and operative probe scintimetry of colorectal carcinoma using technetium-99m-88BV59. J Nucl Med 1995 36: 738–745.

    PubMed  Google Scholar 

  98. Morton JD, Quadri SM, TYang XZ et al. Treatment of refractory end stage Hodgkin’s disease with Yttrium-90 polyclonal antiferritin antibodies. J Immunother 1994; 16(2) 160.

    Article  Google Scholar 

  99. Murray JL, Rosenblum MG, Sobol RE, Bartholomew RM, et al. Radioimmunoimaging in malignant melanoma with mln-labeled monoclonal antibody 96.5. Cancer Res 1985;45:2376–2381.

    PubMed  CAS  Google Scholar 

  100. Murray JL, Rosenblum MG, Lamki L, et al. Clinical parameters related to optimal tumor localization of indium- 111-labeled mouse antimelanoma monoclonal antibody ZME-018 .J Nucl Med 1987; 28: 25–33.

    PubMed  CAS  Google Scholar 

  101. Murray JL, Zukiwski AA, Mujoo K et al. Recombinant alpha-interferon enhances tumor targeting of an anti melanoma monoclonal antibody in vivo. J Biol Response Mod 1990; 4: 556–563.

    Google Scholar 

  102. Murray JL, Macey DJ, Grant EJ, et al. Phase II trial of 131ICC49 Mab plus alpha interferon (rIFN°c) in breast cancer. J Immunother 1994; 16(2) 162 (abs).

    Article  Google Scholar 

  103. Nabi HA, Doerr RJ, Chan H-W, Balu D, Schmelter RF, Maguire RT. In-111-labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma: safety, sensitivity, and preliminary clinical results. Radiology 1990; 175:163–171.

    PubMed  Google Scholar 

  104. Nabi HA, Doerr RJ. Radiolabeled monoclonal antibody imaging (immunoscintigraphy) of colorectal cancers: current status and future perspectives. Amer Journ Surg 1992; 163:448–456.

    Article  CAS  Google Scholar 

  105. Nabi HA, Schwartz AN, Higano CS, et al. Colorectal carcinoma: Detection with indium-1ll anticarcinoembryonic- antigen monoclonal antibody ZCE-025. Radiology 1987; 164: 617–621.

    PubMed  Google Scholar 

  106. Naruki Y, Carrasquillo JA, Reynolds JC, et al. Differential cellular metabolism of In-111, Y-90, and 1-125 radiolabeled T101 anti-CD5 monoclonal antibody. Int J Rad ApplInstrum Br 1990; 17: 201–207.

    CAS  Google Scholar 

  107. Neal CE, Swenson LC, Fanning JC, Texter JH. Monoclonal antibodies in ovarian and prostate cancer. Seminars in Nucl Med 1993; 23(2) 114–126.

    Article  CAS  Google Scholar 

  108. Oldham RK, Foon KA, Morgan AC, et al. Monoclonal antibody therapy of malignant melanoma: In vivo localization in cutaneous metastases after intravenous administration. J Clin Oncol 1984; 2: 1235.

    PubMed  CAS  Google Scholar 

  109. Order SE, Klein JL, Leichner PK, et al. Advances in iodine-131 labeled antiferritin immunoglobulin cancer therapy. Cancer Biol 1982; 34:264–267.

    Google Scholar 

  110. Order SE, Klein JL, Leichner PK. Radiation therapy of hepatoma with 1-131 and Y-90 labeled antiferritin antibodies. Int. Conf. Monoclonal Antibody Immunoconjugates for Cancer 1986; 1: 27–28.

    Google Scholar 

  111. Order SE, Vriesendorp HM, Klein JL, et al. A phase I study of 90yttrium antiferritin: dose escalation and tumor dose. Antibody Immunoconjug Radiopharm 1988; 1(2): 163–168.

    Google Scholar 

  112. Otsuka FL, Welch MJ. Methods to label monoclonal antibodies for use in tumor imaging. Nucl Med Biol 1987; 14: 243–249

    CAS  Google Scholar 

  113. Paganelli G, Malcovati M, Fazio F. Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system. Nucl Med Communications 1991; 12:211–234..

    Article  CAS  Google Scholar 

  114. Paganelli G, Belloni C, Magnani P, et al. Two-step tumor targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med 1992; 19: 322–329.

    Article  PubMed  CAS  Google Scholar 

  115. Paganelli G, Magnani P, Meares C, et al. Antibody guided therapy of CEA positive tumors using biotinylated monoclonal antiodies, avidin, and 90Y -DOTA-biotin: initial evaluation. J Nucl Med 1993; 34(5): 94P.

    Google Scholar 

  116. Patt YZ, Lamki LM, Shanken J, et al. Imaging with indium Ill-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. J Clin Oncol 1990; 8: 1246–1254

    PubMed  CAS  Google Scholar 

  117. Pimm M. Circulating antigen: Bad or good for immunoscintigraphy. Nuc Med Biol 1995; 22: 137–145..

    Article  CAS  Google Scholar 

  118. Pizer BL, PapanastassiouV, Mosely R, Tzanis S, Hancock JP, Kemshead JT, Coakham HB. Meningeal leukemia and medullablastoma: preliminary expeience with intrathecal radioimmunotherapy. Antib Immunoconj Radiopharm 1991; 4(4) 753–761.

    Google Scholar 

  119. Podoloff DA, Patt YZ, Curley SA, Kim EE, Bhadkamkar VA, Smith RE. Imaging of colorectal carcinoma with technetium-99m radiolabeled Fab’ fragments. Seminars in Nucl Med 1993; 23(2) 89–98

    Article  CAS  Google Scholar 

  120. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeledantibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329(17) 1219–1224.

    Article  PubMed  CAS  Google Scholar 

  121. Press OW, Eary JF, Appelbaum FR, Bernstein ID. Radiolabeled antibody therapy of lymphomas. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer 1994; 4(4): 1-13

    Google Scholar 

  122. Press OW, Eary JF, Martin PJ, et al. Preliminary results of a phase II trial of iodine-131 -labeled anti-CD20 (Bl) antibody therapy with bone marrow rescue for patients with relapsed B cell lymphomas. J Immunother 1994; 16(2) 160 (abs).

    Article  Google Scholar 

  123. Rao DV, Howell RW. Time-dose-fractionation in radio immunotherapy: Implications for selecting radionuclides. J Nucl Med 1993; 34: 1801–1810.

    PubMed  CAS  Google Scholar 

  124. Richman CM, DeNardo SJ, O’Grady LF, Valk PE, DeNardo GL. Radioimmunotherapy for breast cancer using escalating fractionated doses of I-131 chimeric (Ch) L6. J Immunother 1994; 16(2) 161 (abs).

    Article  Google Scholar 

  125. Riva P, Arista A, Sturiale, C., Franceschi, G., et al. Direct intratumor radioimmunotherapy of malignant gliomas: clinical experiences in recurrent or primary tumours. J Immunother 1994; 16(2) 163 (abs)

    Article  Google Scholar 

  126. Riva P, Tison G, Franchesci N, Casi M , Moscatelli G. Successful treatment of metastatic gastrointestinal cancer by means of radioimmunotherapy. J Nucl Med 1992; 33(5) 863 Abst.

    Google Scholar 

  127. Rodwell JD, Alvarez VL, Lee C, et al. Site-specific covalent modification of monoclonal antibodies: In vitro and in vivo evaluations. Proc Natl Acad Sci USA 1986; 83: 2632–2636.

    Article  PubMed  CAS  Google Scholar 

  128. Rosen ST, Zimmer AM, Goldman-Leiken et al. Radioimmunodetection and radioimmunotherapy of cutaneous T-cell lymphomas using an 13lI-labeledT101 monoclonal antibody: anlllinios Cancer Council study. J Clin Oncol 1987; (5) 562.. Blood 1986; 68: 241a (abstr).

    PubMed  CAS  Google Scholar 

  129. Rusch V Macapinlac H, Heelan R, et al. NR-LU-10 Monoclonal Antibody Scanning: A Helpful New Adjunct to CT in Evaluating Non-Small Cell Lung Cancer. J Thorac Cardiovasc Surg 1993; 106: 200–204

    PubMed  CAS  Google Scholar 

  130. Sahakara H, Reynolds JC, Carasquillo JA et al. In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med, 1989; 30: 1311–1317.

    Google Scholar 

  131. Salk D and the Multicenter Study Group. Technetiumlabeled monoclonal antibodies for imaging metastatic melanoma: Results of a multicenter clinical study. Semin Oncol 1988; 15:608–618.

    PubMed  CAS  Google Scholar 

  132. Salk D, Lesley T, Wiseman G, et al. A phase I trial of a fractionated dose intraperitoneal administration of Rhenium- 186 monoclonal antibodies in ovarian cancer. Antib Immunoconj Radiopharm 1992; 4: 359 Abst.

    Google Scholar 

  133. Scheinberg DA, Straus DJ, Yeh SD, etc. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-hodgkin’s lymphoma: Effects of tumor burden and antigen expression. Journal of Clinical Oncology 1990; 8(5) 792–803

    PubMed  CAS  Google Scholar 

  134. Schlom J, Molinolo A, Simpson JF et al. Advantages of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 1990; 82: 763–771.

    Article  PubMed  CAS  Google Scholar 

  135. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985; 45: 879–885.

    PubMed  CAS  Google Scholar 

  136. Schwartz MA, Lovett DR, Redner A, et al. Doseescalation trial of Ml 95 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. Journal of Clinical Oncology 1993; 11(2) 294–303.

    PubMed  CAS  Google Scholar 

  137. Schwartz SW, Connett JM, Anderson CJ, Rocque PA, Philpott GW, Guo LW, Welch MJ. Evaluation of a direct method for technetium labeling of intact and F(ab’)2 1 A3, an anticolorectal monoclonal antibody. Nucl Med Biol 1994;21:619–626.

    Article  Google Scholar 

  138. Serafini AN, Kotler J, Feun L, et al. Technetium-99mlabeled monoclonal antibodies in the detection of metastatic melanoma. J Clin Nucl Med 1989; 14: 580–587.

    Article  CAS  Google Scholar 

  139. Siccardi AG, Buraggi GL, Callegaro L, et al. Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. Cancer Res 1986; 46:4817–4822.

    PubMed  CAS  Google Scholar 

  140. Stemmer SM, Johnson R, Kasliwal R, et al. High dose 90Y Mx-DTPA-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer. J Immunother 1994; 16(2) 161 (abs).

    Article  Google Scholar 

  141. Stewart JSW, Hird V, Snook D, et al. Intraperitoneal radioimmunotherapy for ovarian cancer: Pharmacokinetics, toxicity, and efficacy of 1-131 labeled monclonal antibodies. Int J Radiation Oncology Biol Phys 1989; 16:405–413.

    Article  CAS  Google Scholar 

  142. Stickney DR, Slater JB, Kirk GA, et al. Bifunctional antibody: ZCE/CHA 11 indium BLEDTA-IV clinical imaging in colorectal carcinoma. Ant Immun Radiopharm 1989; 2: 1–13.

    Google Scholar 

  143. Sung C, Shockley TR, Morrison PF, Dvorak HF, Yarmush ML, Dedrick RL. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody 150. uptake in solid tumors. Cancer Research 1992; 52: 377–384.

    PubMed  CAS  Google Scholar 

  144. Surwit EA, Childers JM, Krag DN, Katterhagen G, Gallion H, Waggoner S, Mann WJ Jr. Clinical assessment of111 In-CYT-103 immunoscintigraphy in ovarian cancer. Gynecologic Oncology 1993; 48:285–292.

    Article  PubMed  CAS  Google Scholar 

  145. Volkert WA, Goeckeler WF, Ehrhardt GJ, Ketring AR. Therapeutic radionuclides: Production and decay property considerations. J Nucl Med 1991; 32: 174–185.

    PubMed  CAS  Google Scholar 

  146. Waldmann TA, Strober W. Metabolism of immunoglobulin. Prog Allergy 1969; 13: 1–10.

    PubMed  CAS  Google Scholar 

  147. Weiden PL, Breitz HB, Seiler CA, et al. Rhenium-186- labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10. J Nucl Med 1993; 34: 2111–2119.

    PubMed  CAS  Google Scholar 

  148. Weiden PL, Wolf SB, Breitz HB, et al. Human anti-mouse antibody suppression with Cyclosporin A. Cancer 1994; 73(3): 1093–1097

    Article  PubMed  CAS  Google Scholar 

  149. Weinstein JN, Eger RR, Covell DG, et al. The pharmacology of monoclonal antibodies. Ann NY Acad Sci 1987; 507: 199–210.

    Article  PubMed  CAS  Google Scholar 

  150. Wessels BW, Rogers RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 1984; 11: 638–645.

    Article  PubMed  CAS  Google Scholar 

  151. Wessels BW. Current status of animal radioimmunotherapy. Cancer Res 1990; 50: 970s–973s.

    PubMed  CAS  Google Scholar 

  152. Wheldon TE, O’Donoghue JA, Bartett A, Michalowski AS. The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y. Radiotherapy Oncol 1991; 21:91–99.

    Article  CAS  Google Scholar 

  153. Wilbur DS. Radiohalogenation of proteins: an overview of radionuclides, labeling methods and reagents for conjugate labeling. Bioconjugate Chem 1992; 3:433–470.

    Article  CAS  Google Scholar 

  154. Yorke ED, Beaumier PL, Wessels BW, Fritzberg AR, Morgan AC Jr. Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: A predictive model based on mouse pharmacokinetics. Nucl Med Biol 1991; 18:827–835

    CAS  Google Scholar 

  155. Zalutsky MR. Radiohalogenation of antibodies: Chemical aspects. In: Radiolabeled Monoclonal Antibodies for Imaging and Therapy. Srivastava SC, Ed., Plenum Press, New York, 1988.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NeoRx-Virginia Mason Clinical Research Unit, Seattle, WA, USA

    Hazel B. Breitz

  2. Virginia Mason Medical Center, Seattle, WA, USA

    Paul L. Weiden

  3. NeoRx Corporation, Seattle, WA, USA

    Alan R. Fritzberg, John M. Reno & Paul G. Abrams

Authors
  1. Hazel B. Breitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul L. Weiden
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alan R. Fritzberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John M. Reno
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul G. Abrams
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Biological Therapy Institute Foundation, Franklin, Tennessee, USA

    Robert K. Oldham M.D. (Clinical Professor of Medicine) (Clinical Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Breitz, H.B., Weiden, P.L., Fritzberg, A.R., Reno, J.M., Abrams, P.G. (1998). Radiolabeled Monoclonal Antibodies for Localization and Treatment of Metastatic Cancer. In: Oldham, R.K. (eds) Principles of Cancer Biotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0029-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0029-5_15

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6501-6

  • Online ISBN: 978-94-009-0029-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation